These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2550842)

  • 1. Haloperidol pretreatment unmasks the kappa opioid effects of U-50, 488H on cortical EEG and EEG power spectra in rats.
    Young GA; Marquis KL; Paquette NC; Gussio RP; Khazan N
    Neuropharmacology; 1989 Aug; 28(8):881-4. PubMed ID: 2550842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between U-50,488H and sigma receptor antagonists: EEG, EEG power spectral and behavioral correlates.
    Young GA; Hudson GM; Stamidis H; Steinfels GF
    Eur J Pharmacol; 1993 Feb; 231(3):473-6. PubMed ID: 8095467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist.
    Bhargava HN; Ramarao P; Gulati A
    Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective kappa-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action.
    Czlonkowski A; Millan MJ; Herz A
    Eur J Pharmacol; 1987 Oct; 142(1):183-4. PubMed ID: 2826175
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats.
    Fukagawa Y; Katz JL; Suzuki T
    Eur J Pharmacol; 1989 Oct; 170(1-2):47-51. PubMed ID: 2558895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord.
    Bhargava HN; Gulati A; Ramarao P
    J Pharmacol Exp Ther; 1989 Oct; 251(1):21-6. PubMed ID: 2552075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
    Pugsley MK; Penz WP; Walker MJ; Wong TM
    Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of naloxone-sensitive and naloxone-insensitive effects of U-50,488H.
    Young GA
    Pharmacol Biochem Behav; 1989 May; 33(1):215-7. PubMed ID: 2780779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
    Wilson JL; Nayanar V; Walker JS
    Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.
    Yamamoto T; Ohno M; Ueki S
    Eur J Pharmacol; 1988 Oct; 156(1):173-6. PubMed ID: 2850208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of a selective kappa receptor agonist, U-50, 488H, on methamphetamine-elicited ipsilateral circling behavior in rats with unilateral nigral lesions.
    Ohno M; Yamamoto T; Ueki S
    Psychopharmacology (Berl); 1989; 97(2):219-21. PubMed ID: 2543013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural effect of pretreatment with opioid antagonists and sigma binding site ligands on the abnormal motor response produced by the kappa opioid agonist U50,488H in guinea pigs.
    Brent PJ
    Neuropharmacology; 1993 Aug; 32(8):751-60. PubMed ID: 8413839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of central receptors for thyrotropin-releasing hormone in kappa opiate agonist-induced abstinence in the rat.
    Bhargava HN; Gulati A; Rahmani NH
    Neuropharmacology; 1992 Feb; 31(2):137-41. PubMed ID: 1313157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of acute and chronic administration of dizocilpine on the pharmacological responses to U-50,488H and brain and spinal cord kappa-opioid receptors in the rat.
    Bhargava HN; Matwyshyn GA; Gudehithlu KP
    Pharmacology; 1995 Nov; 51(5):323-30. PubMed ID: 8584584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H.
    Ho BY; Takemori AE
    J Pharmacol Exp Ther; 1989 Aug; 250(2):508-14. PubMed ID: 2547935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential neuropharmacological effects of mu, kappa and sigma opioid agonists on cortical EEG power spectra in the rat. Stereospecificity and naloxone antagonism.
    Young GA; Khazan N
    Neuropharmacology; 1984 Oct; 23(10):1161-5. PubMed ID: 6097833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
    Sheldon RJ; Nunan L; Porreca F
    J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of brain and spinal cord K-opiate receptors in spontaneously hypertensive, Wistar-Kyoto normotensive, and Sprague-Dawley rats by chronic treatment with U-50, 488H.
    Bhargava HN; Gulati A; Ramarao P
    Biochem Pharmacol; 1991 Jun; 42(1):25-9. PubMed ID: 1648922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the kappa-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task.
    Ohno M; Yamamoto T; Ueki S
    Eur J Pharmacol; 1991 Feb; 193(3):357-61. PubMed ID: 1647321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.
    Ukai M; Kameyama T
    Brain Res; 1985 Jul; 337(2):352-6. PubMed ID: 2992682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.